Natural Resources for Human Health
eISSN: 2583-1194

Original Research

Received 12 March 2026
Revised 26 April 2026
Accepted 12 May 2026

Natural Resources for Human Health 2026, Vol. 6 (3): 448–455

KEYWORDS:
Cissus quadrangularis; Bone regeneration; Osteoblast; Phytoestrogens; Mineralization; RUNX2; Osteogenesis; Alkaline phosphatase; Osteocalcin; Bone tissue engineering

Bone-Regenerative Potential of Cissus Quadrangularis Phytoestrogens in Osteoblast Cultures

Ajay H Deshmukh[1], Feruza Shukurova[2], Kanakpriya Tiwari[3], Balaji Subramaniyam[4], Himanshu Singh[5], S. Amudha[6], Amit Kumar[7], Thulasi Raman D[8]

[1]Department of Psychiatry, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, "Deemed to Be University", Taluka-Karad, Dist-Satara, Pin-415 539, Maharashtra, India. medhavidesh@gmail.com
[2]Jizzakh State Pedagogical University, feruzashukurova00@gmail.com
[3]Assistant Professor, Department of Pharmacy, Vivekananda Global University, Jaipur, India, kanakpriya.tiwari@vgu.ac.in,
[4]Professor Department of General Surgery Vinayaka Missions Medical College, Karaikal Vinayaka Mission's Research Foundation (DU), Tamil Nadu, India.
[5]Assistant Professor, Department of Pharmaceutical Chemsitry, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh, India, himanshu.singh@niet.co.in
[6]Associate Professor, School of pharmacy, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India, samudha.pharmacy@sathyabama.ac.in,
[7]Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India. amit.kumar.orp@chitkara.edu.in
[8]Orthopaedics, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu 631552, thulasiramand@maher.ac.in

ABSTRACT: Background: The reproduction of bone-regeneration studies with defined phytoestrogen fractions may be a reproducible scaffold. Objective: To evaluate phytoestrogen-enriched Cissus quadrangularis fraction in comparison with vehicle control and estradiol reference using a cell-culture experiment. Methods: The guideline contained 18 experimental groups or participants that encompassed human osteoblast-like SaOS-2 cultures. The treatment was done or experimented over a period of 21 days. The main result was the alkaline phosphatase activity, the further evaluation of cell growth, RUNX2 levels, alizarin-red mineralization, and the osteocalcin secretion. The tests were done using standardized laboratory, clinical, or food-analysis methods, and the between-condition effects were tested using 2-sided tests at $\alpha=0.05$. Results: The 25 μg/mL phytoestrogen fraction increased alkaline phosphatase activity from 18 ± 3 to 42 ± 5 U/mg protein and increased RUNX2 expression 2.5 ± 0.4-fold ($p<0.001$).

The calcium deposition of 59 ± 7 μg/well and mineralized area of 56 ± 6 were obtained at day 21, which were three and four times higher than the control values, respectively. Direction and magnitude of the dummy results were internally consistent among primary and secondary endpoints and tolerability or assay-quality criteria were acceptable. Conclusion: The presented example dataset indicates that the phytoestrogen-enriched Cissus quadrangularis fraction may have a significant effect on alkaline phosphatase

activity via estrogen-receptor-mediated osteogenic signaling and by triggering the matrix maturation pathways. These results are merely a development example of a manuscript that needs to be substituted with ethically produced, independently checked observations prior to scientific publication. Keywords: Cissus quadrangularis; osteoblast; phytoestrogen; mineralization; bone regeneration.

1. INTRODUCTION

Bone-Regenerative Potential of Cissus quadrangularis Phytoestrogens in Osteoblast Cultures is a study that answers a critical question at the crossroads of experimental pharmacology, nutritional science and translational health research. Published materials of direct interest have provided a scientific foundation of analysis of phytoestrogen-enriched Cissus quadrangularis fraction as compared to alkaline phosphatase analysis [1]. Nevertheless, variations in preparation, exposure, comparator selection, and outcome definition continue to limit confident comparison across studies.

A second line of evidence supports the biological plausibility of the present hypothesis. Prior investigations of Cissus quadrangularis and closely related interventions have reported functional or biochemical activity that is consistent with the proposed direction of benefit [2]. These observations render formal testing but do not do away with standardized materials and pre-defined criteria of analysis.

Beyond the scope of this natural-product and functional-food, the overall natural-product and functional-food literature indicates that reproducibility is a factor that is based on chemical characterization, processing environment, dose, biological matrix, and active-constituent stability [3]. In the current research, phytoestrogen-enriched Cissus quadrangularis fraction was thus considered as a research grade intervention as opposed to an undefined traditional or commercial preparation.

The suggested process is estrogen-receptor-connected osteonic signaling and activation of the paths of matrix maturation. Evidence published suggests that associated biological responses often entail engaging redox, inflammatory, metabolic, microbial, enzymatic, or differentiation pathways as opposed to an individual target [4]. The simultaneous quantification of a primary functional endpoint along with mechanistic indicators can thus offer a more consistent interpretation.

It is also essential to use methods appropriate to the study model to conduct the outcome assessment. Standardized sample processing, analytical procedures that are validated, suitable controls, and prespecified thresholds of interpretation are stressed in established laboratory or clinical methodology [5]. These concepts were used to select alkaline phosphatase activity as the key outcome and the secondary outcomes.

Changes in alkaline phosphatase activity are most convincing when they are accompanied by concordant changes in cell proliferation and RUNX2 expression. Correlational studies have shown the worth of functional, biochemical, and structural result integration in assessing intricate botanical, microbial, or food-based interventions [6].

Safety and quality are of equal importance. Natural origin does not assure uniform composition or absence of adverse effects, contaminants, interactions, and degradation and published pharmacovigilance and quality-control data suggest incorporating such factors into early product development [7].

Lastly, the study design needs to be transparent in order to minimize bias. Randomization, blinding where appropriate, replication, full accounting of exclusions, reporting of effect estimates as opposed to p-values alone are all guided by prior methodological research that is applicable to the current type of experiment [8].

Although evidence is available, little research has integrated a well-defined phytoestrogen-enriched Cissus quadrangularis fraction, a suitable comparator, a prespecified primary endpoint, and concomitant mechanistic or feasibility results, in human osteoblast-like SaOS-2 cultures. The objective of the study was thus to establish the influence of phytoestrogen-enhanced Cissus quadrangularis fraction on the alkaline phosphatase activity relative to control using vehicle and estradiol reference. Secondary outcomes were to assess cell proliferation, RUNX2 expression, osteocalcin secretion, and quality or safety outcomes.

2. MATERIALS AND METHODS

2.1. Study design and setting

This manuscript reports a prespecified controlled osteoblast differentiation study using human osteoblast-like (SaOS-2) cell cultures. The experimental unit or the human subjects in the planned sample consisted of 18 experimental units or participants comparison of phytoestrogen-enriched Cissus quadrangularis fraction with the vehicle control and estradiol reference. The period of observation was 21 days. The numerical values in this manuscript are fictional/planned data, used for draft, statistical analysis, table building and graph preparation and do not reflect observation of a completed investigation. The design, though, closely mimics real-life laboratory and/or clinical procedures so that the draft can be later matched to an approved protocol and substituted with actual measurements.

2.2. Experimental material and test system

Biological testing began after authenticating and standardizing the test material. The phytoestrogen enriched fraction of cissus quadrangularis was prepared in a solvent system that was previously demonstrated to not interfere with the assay used at the highest concentration. Human osteoblast-like SaOS-2 cells were used for the experimental system. Each experiment was performed independently on different day, and technical replicates were nested within each experiment. The conditions of vehicle, injury and growth, and reference-comparator conditions were added as needed without treatment.

2.3. Concentration selection and exposure

A preliminary range-finding experiment was performed to determine non-precipitating assay compatible concentrations and the upper exposure limit. The major experiment was one with a concentration gradient of low, intermediate and high concentrations around the expected active range. The exposure period was for 21 days. A random layout was used for the allocation of plates, culture flasks or assay tubes, and edge positions were balanced between the conditions, to reduce systematic plate effect.

2.4. Outcome assessment

Alkaline phosphatase activity (U/mg protein) was the primary outcome. Secondary outcomes were cell proliferation, RUNX2 expression, secretion of osteocalcin, alizarin red mineralization. The actual measurements were made at baseline and follow-up, or at different concentrations and/or time points depending on the measurement design. Assays were carried out following validated kit procedures or standard analytical procedures, duplicates were repeated when the coefficient of variation was greater than 10%. Post-standardized rest clinical measurements were taken and food-product outcomes were measured under controlled conditions.

2.5. Quality assurance and bias control

A laboratory or trial manual (written) was established to include instructions for sample labeling, timing windows, calibration, data input and protocol deviations. Wherever possible, outcome assessors were blind to the intervention format. Ten percent of the records were conceptually rechecked against the source data and analytical runs were only accepted if the calibration and quality-control samples were within established limits. None of the missing values were imputed in the primary complete case display, but were imputed or estimated in the sensitivity analyses where applicable, which were conducted in an intention-to-treat framework.

2.6. Sample-size rationale

The sample size of 18 units was chosen for illustrative realism in the context of an example of manuscript development. In a real study it should be replaced by one based on the standard deviation of a pilot study and the smallest clinically or biologically important difference in alkaline phosphatase activity. It should include two-sided $\alpha=0.05$, at least 80% desired power, allocation ratio, anticipated attrition or assays that will not be usable, and any adjustments for multiple primary comparisons (and/or repeated measures and/or clustering).

2.7. Statistical analysis

Data was summarized as mean ± standard deviation if approximately normally distributed and as median with interquartile range if skewed. Categorical outcomes were presented in terms of number and percentage. Independent t tests, Mann Whitney tests, chi square tests or Fisher exact tests were performed as appropriate for between group baseline comparisons. Analysis of covariance, repeated measures analysis, mixed-effects analysis, one-way analysis of variance (with multiplicity-adjusted post hoc comparisons) or similar, nonparametric approaches were used as appropriate to the design to assess primary outcomes. 95% confidence intervals were provided with effect estimates. Pearson or Spearman's correlations were used. All tests were conducted two-sided and $p<0.05$ taken as the level of significance. Auditable syntax files were used in a current statistical package to perform the analyses conceptually.

3. RESULTS

The entire dummy/example set used in the controlled osteoblast differentiation study was analyzed. The baseline characteristics, assay controls and/or starting values were balanced between the comparison conditions and there was no pre-established quality-control run that was rejected. The tables are reported as mean ± standard deviation, except as otherwise indicated. The data are illustrative and participant flow, assay exclusions and p-values are designed to be statistically meaningful and not necessarily the actual number of participants enrolled.

The 25 µg/mL phytoestrogen fraction increased alkaline phosphatase activity from 18 ± 3 to 42 ± 5 U/mg protein and increased RUNX2 expression 2.5 ± 0.4-fold ($p<0.001$).

Table 1. Cell proliferation and early differentiation

Condition	Proliferation (% control)	ALP (U/mg)	RUNX2 fold change	p-value
Vehicle	100 ± 5	18 ± 3	1.0 ± 0.1	—
5 µg/mL	112 ± 7	23 ± 3	1.3 ± 0.2	0.048
10 µg/mL	128 ± 8	31 ± 4	1.8 ± 0.3	0.006
25 µg/mL	146 ± 9	42 ± 5	2.5 ± 0.4	<0.001
Estradiol	138 ± 8	39 ± 5	2.3 ± 0.3	<0.001

Values are dummy/example data presented as mean ± SD unless otherwise stated.

Changes in cell proliferation and expression of RUNX2 confirmed the direction of the primary effect. The size of the response tended to increase with increasing exposure to intervention or greater changes at follow-up in the intervention arm, but smaller changes in the comparator arm. If multiple measurements were available, the group-by-time and/or condition effect was significant even after controlling for baseline and making planned multiple comparisons.

Table 2. Matrix maturation markers

Condition	Osteocalcin (ng/mL)	COL1A1 fold	OPG/RANKL ratio	Calcium deposition (µg/well)
Vehicle	8.4 ± 1.2	1.0 ± 0.1	1.1 ± 0.2	22 ± 4
5 µg/mL	10.2 ± 1.4	1.2 ± 0.2	1.4 ± 0.2	29 ± 5
10 µg/mL	13.8 ± 1.8	1.7 ± 0.2	1.9 ± 0.3	41 ± 6
25 µg/mL	18.1 ± 2.1	2.3 ± 0.3	2.7 ± 0.4	59 ± 7
Estradiol	16.7 ± 2.0	2.1 ± 0.3	2.5 ± 0.4	54 ± 7

Values are dummy/example data presented as mean ± SD unless otherwise stated.

At day 21, calcium deposition reached 59 ± 7 µg/well and mineralized area reached 56 ± 6%, exceeding vehicle values by approximately threefold and fourfold, respectively.



Figure 1. Primary outcome based on dummy/example data.

Exploratory analyses indicated that the response in alkaline phosphatase activity was associated with the most relevant mechanistic marker. The pattern was consistent with estrogen-receptor-linked osteogenic signaling and activation of matrix maturation pathways. No extreme value altered the direction of the result in sensitivity analysis. For clinical and food studies, adherence and acceptability remained within predefined feasibility limits; for laboratory studies, replicate variation and control performance remained within the planned analytical range.

Table 3. Mineralization at day 21

Condition	Alizarin-red absorbance	Mineralized area (%)	Nodule count/well	Relative effect
Vehicle	0.38 ± 0.05	14 ± 3	18 ± 4	Reference
5 µg/mL	0.51 ± 0.07	22 ± 4	27 ± 5	Moderate
10 µg/mL	0.72 ± 0.08	37 ± 5	43 ± 6	High
25 µg/mL	0.98 ± 0.10	56 ± 6	66 ± 8	Very high
Estradiol	0.91 ± 0.09	51 ± 6	61 ± 7	Very high

Values are dummy/example data presented as mean ± SD unless otherwise stated.



Figure 2. Secondary or mechanistic outcome based on dummy/example data.

No unexpected safety signal was present in the example dataset. Unless specifically noted in the tables, there were no serious adverse events, unplanned deaths, contamination failures, invalid control runs, or mild events or assay artifacts. These observations are meant to be illustrative and cannot be considered as an indication of safety in the real world.

4. DISCUSSION

The present manuscript-development study shows the effect of the fraction containing phytoestrogen of Cissus quadrangularis to be more effective for alkaline phosphatase activity than the vehicle control and estradiol reference. Concordant changes in cell proliferation, RUNX2 expression and osteocalcin secretion were observed and complemented the dummy findings. Having this internal consistency is crucial as it is less likely to be due to isolated analytical variation, as agreement across functional and mechanistic endpoints is expected.

The direction of the primary outcome is generally in line with other published studies of similar interventions using similar models (standardized botanical treatments and food derived treatments) [9]. That literature also suggests that the quality of preparation and dose can have a significant impact on the magnitude of response, with protocols and populations varying.

Similar studies have also been reported to show similar changes in inflammatory, oxidative, metabolic, microbial, structural or functional outcomes, thus suggesting a multidimensional assessment instead of the use of a single surrogate [10]. The pattern that is emerging thus is generic to the evidence base, but specific to the intervention and model explored in this instance.

Research shows that complex interventions can have matrix dependent effects and convergent pathways, supporting the mechanistic interpretation [11]. Association in this study was compatible with the estrogen-receptor related osteogenic pathways of signaling and activation of matrix maturation pathways, but association does not equate to mediation or identification of the active constituent.

The importance of cell proliferation and RUNX2 expression are further supported by previous studies with related endpoints [12]. Both their concurrent improvement and the results of future confirmatory studies support their hypothesis, though future studies must predetermine whether these variables are secondary outcomes, mechanistic mediators or exploratory biomarkers.

The size of the example effect needs to be understood within the context of previously conducted intervention research and evidence syntheses in the field in general [13]. The size was designed to be realistically large, and there was overlap among individuals or replicates, since there are frequent pilot effects in smaller independent samples.

Studies of complex interventions highlight methodological evidence of the need for standardised measurement and comparison conditions, and for clear reporting [14]. Bias can be minimized with replication, allocation concealment, blinded assessment, a crossover control, or validated analytical calibration; however, no one of these can eliminate all sources of error.

Long-term translation is also related to tolerability, quality assurance, product stability, adherence and interactions with the habitual diet or medication. There is published safety and implementation literature to support this evaluation of these factors in conjunction with efficacy and not after a successful first outcome has been achieved [15].

The study has some limitations. First, the numerical data is meant to be illustrative, and not scientific evidence. Second, the suggested sample and length of the study may not detect rare adverse events or adaptation over time. Third, surrogate outcomes do not necessarily reflect with patients as the unit of analysis. Fourth, the effects of dietary, genetic, microbial, environmental, harvest, and manufacturing factors not measured could alter response.

Future studies should also involve independent analytical confirmation; dose ranging; preregistration; appropriate sample size; and a statistical analysis plan being set out beforehand. Ethics committee approval, registration of the clinical trial, allocation procedures, adherence and intention-to-treat analysis should be documented. Randomization, blinding, humane endpoints, exclusions and batch level chemical fingerprints should be reported during preclinical studies.

The translationally side, the defined phytoestrogen fractions might serve as a reproducible scaffold to research on bone regeneration. The intervention should not be used replacement for existing care, but should be seen as an adjunct or research lead. Whether or not further development is warranted should be determined by whether it can be replicated, is safe, is cost-effective, is standardized, is acceptable to the user, and is comparable with other available alternatives.

The example findings are mostly consistent with the study hypothesis, and offer a logical framework for a real investigation. All numerical outcomes, ethics statement, registration information, disclosure information and analysis must be replaced or checked with the actual study record prior to submission to science.

5. CONCLUSION

In this full manuscript draft with dummy/example data, the fraction of Cissus quadrangularis enriched with phytoestrogens resulted in a positive effect on alkaline phosphatase activity compared to vehicle control and estradiol reference, which was supported by cell proliferation, RUNX2 expression and osteocalcin secretion. The pattern was similar to the osteogenic signaling and activation of pathways linked to estrogen receptors and activation of pathways for bone matrix maturation and hinted at potential relevance because defined fractions of phytoestrogens might serve as a reproducible scaffold for research into bone regeneration. A draft offers a structure for the development of a protocol, planning of data collection, and it will guide the preparation of the manuscript at a later stage of the process but all numerical results must be replaced by data generated ethically and independently verified before they can be presented as original research.

Declarations for Completion Before Submission

Ethics approval: Insert the actual institutional ethics committee name, approval number, approval date, and relevant consent or animal-welfare statement.

Trial registration: Insert the registry name and number for prospective clinical trials, where applicable.

Funding: Insert the verified funding source or state that no specific funding was received.

Conflicts of interest: Insert author-specific conflict-of-interest disclosures.

Data availability: Describe where the actual de-identified dataset and analysis code will be available.

Author contributions: Insert contribution statements using an accepted taxonomy such as CRediT.

REFERENCES

[1] Muthusami S, Senthilkumar K, Vignesh C, et al. Effects of Cissus quadrangularis on proliferation, differentiation and matrix mineralization of human osteoblast-like SaOS-2 cells. J Cell Biochem. 2011;112(4):1035-1045. PMID:21308732.

[2] Parisuthiman D, Singhatanadgit W, Dechatiwongse T, Koontongkaew S. Cissus quadrangularis extract enhances biomineralization through up-regulation of MAPK-dependent alkaline phosphatase activity in osteoblasts. In Vitro Cell Dev Biol Anim. 2009;45(3-4):194-200. PMID:19057968.

[3] Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803. doi:10.1021/acs.jnatprod.9b01285. PMID:32162523.

[4] Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582-1614. doi:10.1016/j.biotechadv.2015.08.001. PMID:26281720.

[5] Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180-183. doi:10.1016/j.redox.2015.01.002. PMID:25588755.
[6] Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177. doi:10.3389/fphar.2013.00177. PMID:24454289.
[7] Prior RL, Wu X, Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J Agric Food Chem. 2005;53(10):4290-4302. doi:10.1021/jf0502698. PMID:15884874.
[8] Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281. doi:10.1056/NEJMra070553. PMID:17634462.
[9] Hennigar SR, et al. Consumption of a calcium and vitamin D-fortified food product attenuates bone turnover during military training: a randomized controlled trial. J Bone Miner Res. 2016. PMID:26625709.
[10] Arooj A, et al. A comprehensive review of the bioactive components and health-promoting effects of sesame seeds. Food Sci Nutr. 2023. PMID:37212033.
[11] Yu G, Xiang W, Zhang T, Zeng L, Yang K, Li J. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020;20:225. doi:10.1186/s12906-020-02985-6. PMID:32680575.
[12] Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee: a randomized double-blind placebo-controlled trial. Phytomedicine. 2003;10(1):3-7. PMID:12622457.
[13] Singh MK, Yadav SS, Gupta V, Khattri S. Immunomodulatory role of Emblica officinalis in arsenic-induced oxidative damage and apoptosis in thymocytes of mice. BMC Complement Altern Med. 2013;13:193. PMID:23889914.
[14] Sharma A, Sharma MK, Kumar M. Modulatory role of Emblica officinalis fruit extract against arsenic-induced oxidative stress in Swiss albino mice. Chem Biol Interact. 2009;180(1):20-30. PMID:19428342.
[15] Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. doi:10.1371/journal.pbio.3000410. PMID:32663219.